NuGenerex Immuno-oncology, Inc. (NGIO)

Chart not available yet

Market Cap	952.70M
Revenue (ttm)	n/a
Net Income (ttm)	-4.63M
Shares Out	105.86M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings Date	n/a

About NGIO

NuGenerex Immuno-oncology is focused on the regulation of the immune system to treat cancer and infectious diseases. To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key. With the Ii-Key vaccine technology, we are able to activate the immune system against target molecules, whether those targets are tumor associated antigens (TAAs) in cancer cells, or viral or bacterial proteins in infectious disease pathogens. Through our 20+ year history of research and developme...

• Industry: Pharmaceutical Preparations
• IPO Date: Pending
• CEO: Joseph Moscato
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: NGIO

Full Company Profile

Financial Performance

Financial Statements

News

NuGenerex Immuno-oncology IPO Registration Document (S-1)

NuGenerex Immuno-oncology, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC